Vetr lowered shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) from a hold rating to a sell rating in a research report report published on Monday, July 24th. The brokerage currently has $28.85 price objective on the biopharmaceutical company’s stock.
JUNO has been the topic of several other reports. Cowen and Company reissued a buy rating and set a $36.00 price target (down from $41.00) on shares of Juno Therapeutics in a research report on Thursday, March 30th. Leerink Swann reissued an outperform rating on shares of Juno Therapeutics in a research report on Monday, June 12th. Citigroup Inc. dropped their price target on Juno Therapeutics from $34.00 to $30.00 and set a buy rating on the stock in a research report on Tuesday, April 4th. Zacks Investment Research raised Juno Therapeutics from a hold rating to a buy rating and set a $32.00 price target on the stock in a research report on Tuesday, July 11th. Finally, BidaskClub lowered Juno Therapeutics from a buy rating to a hold rating in a research report on Saturday, June 10th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Juno Therapeutics currently has an average rating of Hold and an average target price of $30.63.
Juno Therapeutics (JUNO) opened at 26.99 on Monday. Juno Therapeutics has a 1-year low of $17.52 and a 1-year high of $34.35. The company has a 50-day moving average of $28.75 and a 200 day moving average of $24.87. The stock’s market cap is $2.83 billion.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.72) by $0.24. The business had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The firm’s quarterly revenue was down 22.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.64) earnings per share. Analysts predict that Juno Therapeutics will post ($3.13) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was first reported by BNB Daily and is the property of of BNB Daily. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.baseball-news-blog.com/2017/08/19/juno-therapeutics-inc-nasdaqjuno-downgraded-to-sell-at-vetr-inc-updated-updated-updated.html.
In related news, Director Anthony B. Evnin purchased 9,000 shares of the firm’s stock in a transaction dated Tuesday, June 20th. The stock was bought at an average price of $24.40 per share, for a total transaction of $219,600.00. Following the purchase, the director now owns 66,301 shares in the company, valued at approximately $1,617,744.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Steve Harr sold 8,750 shares of the stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $30.00, for a total value of $262,500.00. Following the sale, the chief financial officer now owns 736,189 shares of the company’s stock, valued at approximately $22,085,670. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,053,500 shares of company stock valued at $217,594,440. 15.26% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the stock. Capital Fund Management S.A. acquired a new stake in shares of Juno Therapeutics during the first quarter valued at $1,087,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Juno Therapeutics during the first quarter valued at $1,063,000. First Trust Advisors LP increased its stake in shares of Juno Therapeutics by 47.1% in the first quarter. First Trust Advisors LP now owns 1,377,667 shares of the biopharmaceutical company’s stock valued at $30,570,000 after buying an additional 440,984 shares during the last quarter. Great West Life Assurance Co. Can increased its stake in shares of Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 3,800 shares during the last quarter. Finally, Canada Pension Plan Investment Board increased its stake in shares of Juno Therapeutics by 111.2% in the first quarter. Canada Pension Plan Investment Board now owns 94,400 shares of the biopharmaceutical company’s stock valued at $2,095,000 after buying an additional 49,700 shares during the last quarter. Hedge funds and other institutional investors own 65.03% of the company’s stock.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.